<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03007147</url>
  </required_header>
  <id_info>
    <org_study_id>AALL1631</org_study_id>
    <secondary_id>NCI-2016-01588</secondary_id>
    <secondary_id>AALL1631</secondary_id>
    <secondary_id>AALL1631</secondary_id>
    <secondary_id>AALL1631</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <nct_id>NCT03007147</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</brief_title>
  <official_title>International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies how well imatinib mesylate and combination
      chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive
      acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by
      blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in
      different ways to stop the growth of cancer cells, either by killing the cells, by stopping
      them from dividing, or by stopping them from spreading. Giving imatinib mesylate and
      combination chemotherapy may work better in treating patients with Philadelphia chromosome
      positive acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare disease-free survival (DFS) of standard risk pediatric Philapdelphia
      chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib
      mesylate (imatinib) combined with either a high-risk Children's Oncology Group
      (COG)/Berlin-Frankfurt-Munster (BFM) ALL chemotherapy backbone or the more intensive
      European (Es)PhALL chemotherapy backbone.

      SECONDARY OBJECTIVES:

      I. To determine the feasibility of administration of imatinib after allogeneic hematopoietic
      stem cell transplantation (HSCT) in high risk Ph+ ALL patients.

      II. To determine disease-free survival (DFS) of high risk pediatric Ph+ ALL patients treated
      with EsPhALL chemotherapy, HSCT in first complete remission and post-HSCT imatinib.

      III. To compare rates of grade 3 or higher infections in standard risk Ph+ ALL patients
      between the two randomized arms.

      TERTIARY OBJECTIVES:

      I. To describe the toxicities associated with post-HSCT administration of imatinib.

      II. To evaluate the long-term toxicities in patients treated with chemotherapy plus imatinib
      (no transplant), and explore the differences between arms.

      III. To determine prognostic significance of minimal residual disease (MRD) in Ph+ ALL at
      various time points during therapy.

      IV. To determine the prognostic significance of MRD at end of Induction IA. V. To evaluate
      MRD during post-Induction IB therapy in standard risk (SR) patients and explore whether
      there are any differences between randomized arms in the proportion of patients with
      non-detectable MRD at each time point.

      VI. To evaluate MRD in high risk (HR) patients just prior to HSCT and then at regular
      intervals post-HSCT and explore the association of these measurements with long-term
      outcome.

      VII. To evaluate concordance of MRD assessments made by immunoglobulin heavy chain (IGH)-T
      cell receptor (TCR) polymerase chain reaction (PCR) assay and next generation sequencing
      (NGS) assays.

      VIII. To determine prognostic significance of IKZF1 gene aberrations and deletions.

      IX. To determine frequency and prognostic significance of p210 BCR-ABL1 fusion variants in
      pediatric Ph+ ALL.

      X. To measure adherence to oral chemotherapeutic agents (imatinib, 6-mercaptopurine, and
      methotrexate) for 6 months during the maintenance phase in standard risk Ph+ ALL patients.

      XI. To identify factors associated with poor adherence. XII. To determine association
      between relapse risk and adherence to each oral chemotherapeutic agent (separately and
      combined).

      XIII. To measure adherence to imatinib after allogeneic HSCT in high risk Ph+ ALL patients
      and identify factors associated with poor adherence.

      OUTLINE:

      INDUCTION IA PART 1: Patients receive induction IA according to standard of care on days
      1-14.

      INDUCTION IA PART 2: Patients receive imatinib mesylate orally (PO) once daily (QD) on days
      15-33, prednisolone PO twice daily (BID) or methylprednisolone intravenously (IV) on days
      15-28, vincristine sulfate IV over 1 minute on days 15 and 22, daunorubicin hydrochloride IV
      over 1-15 minutes on days 15 and 22, and methotrexate intrathecally (IT) on day 29.

      INDUCTION IB: Patients receive imatinib mesylate PO QD on days 1-35, cyclophosphamide IV
      over 30-60 minutes on days 1 and 28, mercaptopurine PO on days 1-28, cytarabine IV or
      subcutaneously (SC) on days 1-4, 8-11, 15-18, and 22-25, and methotrexate IT on days 8 and
      22.

      POST-INDUCTION THERAPY: Patients with standard risk are randomized to 1 of 2 arms. Patients
      with high risk are assigned to Arm C.

      ARM A:

      CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate PO QD on days 1-21, methotrexate
      IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV
      over 24 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 6, dexamethasone
      PO BID or IV on days 1-5, cyclophosphamide IV over 30-60 minutes on days 2-4, leucovorin
      calcium PO or IV on days 3 and 4, high dose cytarabine IV over 3 hours and pegaspargase IV
      over 1-2 hours on day 5, and filgrastim SC on days 7-11 in the absence of disease
      progression or unexpected toxicity.

      CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate PO QD on days 1-21, methotrexate
      IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV
      over 24 hours on day 1, dexamethasone PO BID or IV on days 1-5, vincristine sulfate IV over
      1 minute on days 1 and 6, ifosfamide IV over 1 hour and mesna IV on days 2-4, leucovorin
      calcium PO or IV on days 3 and 4, dexrazoxane hydrochloride IV over 5-15 minutes and
      daunorubicin hydrochloride IV over 1-15 minutes on day 5, pegaspargase IV over 1-2 hours on
      day 6, and filgrastim SC on days 7-11 in the absence of disease progression or unexpected
      toxicity.

      CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate PO QD on days 1-21, high dose
      cytarabine IV over 3 hours on days 1-3, dexamethasone PO BID or IV on days 1-5, etoposide IV
      over 1-2 hours on days 3-5, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone
      IT on day 5, pegaspargase IV over 1-2 hours on day 6, and filgrastim SC on days 7-11 in the
      absence of disease progression or unexpected toxicity.

      DELAYED INTENSIFICATION 1 PART 1: Patients receive imatinib mesylate PO QD on days 1-35,
      methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine
      sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 5-15 minutes, and doxorubicin IV
      over 1-15 minutes on days 8, 15, 22, and 29, and pegaspargase IV over 1-2 hours on day 8 in
      the absence of disease progression or unexpected toxicity.

      DELAYED INTENSIFICATION 1 PART 2: Patients receive imatinib mesylate PO QD on days 36-63,
      cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine
      IV over 1-30 minutes or SC on days 36-39 and 43-46, and methotrexate IT on days 36 and 43 in
      the absence of disease progression or unexpected toxicity.

      INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD on days 1-28, methotrexate PO
      on days 1, 8, 15, and 22, and mercaptopurine PO on days 1-28 in the absence of disease
      progression or unexpected toxicity.

      DELAYED INTENSIFICATION 2 PART 1: Patients receive imatinib mesylate PO QD on days 1-35,
      methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine
      sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 5-15 minutes, and doxorubicin IV
      over 1-15 minutes on days 8, 15, 22, and 29, and pegaspargase IV over 1-2 hours on day 8 in
      the absence of disease progression or unexpected toxicity.

      DELAYED INTENSIFICATION 2 PART 2: Patients receive imatinib mesylate PO QD on days 36-49,
      cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine
      IV over 1-30 minutes or SC on days 36-39 and 43-46, and methotrexate IT on days 36 and 43 in
      the absence of disease progression or unexpected toxicity.

      MAINTENANCE: Patients receive imatinib mesylate PO QD on days 1-84, methotrexate PO once
      weekly (QW) and IT on days 1 and 43 of courses 1, 2, and 3, and mercaptopurine PO on days
      1-84. Courses with imatinib mesylate and mercaptopurine repeat every 84 days for up to 104
      weeks from the start of Induction IA in the absence of disease progression or unexpected
      toxicity.

      ARM B:

      INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD on days 1-63, vincristine
      sulfate IV over 1 minute and high dose methotrexate IV over 24 hours on days 1, 15, 29, and
      43, leucovorin calcium PO or IV on days 3 and 4, mercaptopurine PO on days 1-56, and
      methotrexate IT on days 1 and 29 in the absence of disease progression or unexpected
      toxicity.

      DELAYED INTENSIFICATION PART 1: Patients receive imatinib mesylate PO QD on days 1-28,
      methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine
      sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 5-15 minutes, and doxorubicin IV
      over 1-15 minutes on days 1, 8, and 15, and pegaspargase IV over 1-2 hours on day 4 in the
      absence of disease progression or unexpected toxicity.

      DELAYED INTENSIFICATION PART 2: Patients receive imatinib mesylate PO QD on days 29-56,
      cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO on days 29-42, cytarabine
      IV over 1-30 minutes or SC on days 29-32 and 36-39, methotrexate IT on days 29 and 36,
      vincristine sulfate IV over 1 minute on days 43 and 50, and pegaspargase IV over 1-2 hours
      on day 43 in the absence of disease progression or unexpected toxicity.

      INTERIM MAINTENANCE WITH CAPIZZI METHOTREXATE: Patients receive imatinib mesylate PO QD on
      days 1-56, vincristine sulfate IV over 1 minute and methotrexate IV over 2-15 minutes on
      days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and pegaspargase IV over 1-2
      hours on days 2 and 22 in the absence of disease progression or unexpected toxicity.

      MAINTENANCE: Patients receive imatinib mesylate PO QD on days 1-84, vincristine sulfate IV
      over 1 minute on days 1, 29, and 57, prednisolone PO BID (or methylprednisolone IV for
      course 1 and 2) on days 1-5, 29-33, and 57-61, mercaptopurine PO on days 1-84, methotrexate
      PO QW, and methotrexate IT on day 1 (and day 29 for course 1 and 2). Courses repeat every 84
      days for up to 104 weeks from the start of Induction IA in the absence of disease
      progression or unexpected toxicity.

      ARM C:

      CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate, methotrexate, cytarabine,
      therapeutic hydrocortisone, high dose methotrexate, vincristine sulfate, dexamethasone,
      leucovorin calcium, high dose cytarabine, and pegaspargase as in Arm A Consolidation Block
      1, and filgrastim SC on day 7 in the absence of disease progression or unexpected toxicity.

      CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate, methotrexate, cytarabine,
      therapeutic hydrocortisone, high dose methotrexate, dexamethasone, vincristine sulfate,
      ifosfamide, leucovorin calcium, dexrazoxane hydrochloride, daunorubicin hydrochloride,
      pegaspargase, and filgrastim as Arm A Consolidation Block 2 in the absence of disease
      progression or unexpected toxicity.

      CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate, dexamethasone, etoposide,
      methotrexate, cytarabine, therapeutic hydrocortisone, pegaspargase, and filgrastim as in Arm
      A Consolidation Block 3, and high dose cytarabine IV over 3 hours on days 1-2 in the absence
      of disease progression or unexpected toxicity.

      HSCT: Patients undergo HSCT on day 0. Patients who do not proceed to HSCT receive Delayed
      Intensification 1, Interim Maintenance, Delayed Intensification 2, and Maintenance as in Arm
      A.

      POST-HSCT: Patients receive imatinib mesylate PO QD starting on days 56-365 in the in the
      absence of disease progression or unexpected toxicity.

      After completion of study treatment, patients are followed up every year for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will compare the DFS of standard risk Ph+ ALL patients treated continuous imatinib mesylate with high risk COG/BFM ALL chemotherapy backbone or more intensive EsPhALL chemotherapy backbone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DFS of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The 3-year DFS for these patients will be estimated with a maximum standard error of 0.053.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imatinib mesylate administration after allogeneic HSCT in high risk Ph+ ALL patients</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Feasibility of post-HSCT imatinib mesylate is determined based on the proportion of patients who receive at least 75% of intended doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms evaluated according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The rate of infections during the post IB/pre-maintenance phases of treatment will be compared accounting for follow-up time.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adherence to imatinib mesylate after allogeneic HSCT in high risk Ph+ ALL patients</measure>
    <time_frame>Up to 12 months post-HSCT</time_frame>
    <description>Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence to oral chemotherapeutic agents in standard risk Ph+ ALL patients</measure>
    <time_frame>Up to day 168 of maintenance phase</time_frame>
    <description>Adherence to imatinib mesylate, 6-mercaptopurine, and methotrexate will be evaluated in COG-enrolled participants using an electronic monitoring device. Adherence rate will be computed for each month of adherence monitoring. Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the work</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of p210 BCR-ABL1 fusion variants</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>For both SR and HR risk groups, frequencies and prognostic significance (OS, DFS) will be explored for p210 BCR-ABL1 fusion variants in pediatric Ph+ ALL.</description>
  </other_outcome>
  <other_outcome>
    <measure>IKZF1 gene aberrations and deletions</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>For both SR and HR risk groups, frequencies and prognostic significance (OS, DFS) will be explored for IKZF1 gene aberrations and deletions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of long-term toxicities in patients treated with chemotherapy plus imatinib mesylate (no transplant) in both arms evaluated according to NCI CTCAE version 4.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Frequencies of long-term toxicities will be described and differences between randomized arms will be explored. Specific long-term toxicities to be explored include cardiac (echocardiographic abnormalities, including decreased left ventricular (LV) function and decreased LV wall thickness), growth (linear height, bone age), and second malignant neoplasm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of toxicities associated with post-HSCT administration of imatinib mesylate evaluated according to NCI CTCAE version 4.0</measure>
    <time_frame>Up to 1 year post-HSCT</time_frame>
    <description>Frequencies of target toxicities in HR patients after the initiation of post-HSCT imatinib mesylate will be described. For the HR patients, the specific targeted toxicities will include grade 4 neutropenia, grade 4 thrombocytopenia, grade 3 or higher bilirubin, grade 4 or higher transaminitis, and grade 3 or higher infection.</description>
  </other_outcome>
  <other_outcome>
    <measure>MRD assessments made by IGH-TCR PCR assay and NGS assay</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Concordance of MRD assessments made by IGH-TCR PCR assay and NGS assay will be described and evaluated. Scatter plots and diagrams will be used to examine agreements and patterns of agreement or any differences found. Concordance will be explored both for the overall cohort, as well as by risk group. The increased sensitivity of the NGS will be closely examined to find cases where the MRD levels are detectable by NGS but undetectable by PCR, as well as cases in which one test yields results and the other does not (test failure). Prognostic relationships on outcomes for these subjects will be i</description>
  </other_outcome>
  <other_outcome>
    <measure>MRD in HR patients measured by IGH-TCR PCR and NGS assay</measure>
    <time_frame>Up to 12 months post-HSCT</time_frame>
    <description>The outcome of HR patients will be described, including proportion of patients who achieve MRD-negativity just prior to HSCT, and at regular intervals post-HSCT. Associations between these findings and long-term outcomes (e.g., OS, DFS) will be explored.</description>
  </other_outcome>
  <other_outcome>
    <measure>MRD in SR patients measured by IGH-TCR PCR and NGS assay</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The proportion of patients with detectable MRD will be described, and association between MRD levels at later time points and long-term outcomes (e.g., DFS and OS) will be explored. The proportion of SR patients in each of the randomized arms at each of the time points who are not MRD-negative (i.e., MRD non-detectable), or who revert to MRD-positive (i.e., MRD value &gt;= 5 x 10^-4) after previously attaining MRD-negative status will also be explored. Odds ratio estimates comparing the rates of not being MRD-negative at start of delayed intensification phase or MRD-positive at any subsequent mon</description>
  </other_outcome>
  <other_outcome>
    <measure>MRD measured by IGH-TCR PCR and NGS assay</measure>
    <time_frame>At the end of induction IA</time_frame>
    <description>For both SR and HR risk groups, frequencies and prognostic significance (overall survival [OS], DFS) will be explored for MRD negativity (&lt; 5 x 10^-4) at end of Induction IA.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1</condition>
  <condition>BCR-ABL1 Fusion Protein Expression</condition>
  <condition>Minimal Residual Disease</condition>
  <condition>Philadelphia Chromosome Positive</condition>
  <condition>T Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo HSCT</description>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV, SC, or IT</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>Cloridrato de Daunorubicina</other_name>
    <other_name>Daunoblastin</other_name>
    <other_name>Daunoblastina</other_name>
    <other_name>Daunoblastine</other_name>
    <other_name>Daunomycin Hydrochloride</other_name>
    <other_name>Daunomycin, hydrochloride</other_name>
    <other_name>Daunorubicin.HCl</other_name>
    <other_name>Daunorubicini Hydrochloridum</other_name>
    <other_name>FI-6339</other_name>
    <other_name>Ondena</other_name>
    <other_name>RP-13057</other_name>
    <other_name>Rubidomycin Hydrochloride</other_name>
    <other_name>Rubilem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Cardioxane</other_name>
    <other_name>Totect</other_name>
    <other_name>Zinecard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Filgrastim XM02</other_name>
    <other_name>Filgrastim-sndz</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tbo-filgrastim</other_name>
    <other_name>Tevagrastim</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Asta Z 4942</other_name>
    <other_name>Asta Z-4942</other_name>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>Holoxane</other_name>
    <other_name>Ifex</other_name>
    <other_name>IFO</other_name>
    <other_name>IFO-Cell</other_name>
    <other_name>Ifolem</other_name>
    <other_name>Ifomida</other_name>
    <other_name>Ifomide</other_name>
    <other_name>Ifosfamidum</other_name>
    <other_name>Ifoxan</other_name>
    <other_name>IFX</other_name>
    <other_name>Iphosphamid</other_name>
    <other_name>Iphosphamide</other_name>
    <other_name>Iso-Endoxan</other_name>
    <other_name>Isoendoxan</other_name>
    <other_name>Isophosphamide</other_name>
    <other_name>Mitoxana</other_name>
    <other_name>MJF 9325</other_name>
    <other_name>MJF-9325</other_name>
    <other_name>Naxamide</other_name>
    <other_name>Seromida</other_name>
    <other_name>Tronoxal</other_name>
    <other_name>Z 4942</other_name>
    <other_name>Z-4942</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>CGP57148B</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
    <other_name>STI 571</other_name>
    <other_name>STI-571</other_name>
    <other_name>STI571</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium Leucovorin</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>Citrovorum Factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Factor, Citrovorum</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>FOLI-cell</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folidan</other_name>
    <other_name>Folidar</other_name>
    <other_name>Folinac</other_name>
    <other_name>Folinate Calcium</other_name>
    <other_name>folinic acid</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folinoral</other_name>
    <other_name>Folinvit</other_name>
    <other_name>Foliplus</other_name>
    <other_name>Folix</other_name>
    <other_name>Imo</other_name>
    <other_name>Lederfolat</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>leucovorin</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>3H-Purine-6-thiol</other_name>
    <other_name>6 MP</other_name>
    <other_name>6 Thiohypoxanthine</other_name>
    <other_name>6 Thiopurine</other_name>
    <other_name>6-Mercaptopurine</other_name>
    <other_name>6-Mercaptopurine Monohydrate</other_name>
    <other_name>6-MP</other_name>
    <other_name>6-Purinethiol</other_name>
    <other_name>6-Thiopurine</other_name>
    <other_name>6-Thioxopurine</other_name>
    <other_name>6H-Purine-6-thione, 1,7-dihydro- (9CI)</other_name>
    <other_name>7-Mercapto-1,3,4,6-tetrazaindene</other_name>
    <other_name>Alti-Mercaptopurine</other_name>
    <other_name>Azathiopurine</other_name>
    <other_name>BW 57-323H</other_name>
    <other_name>Flocofil</other_name>
    <other_name>Ismipur</other_name>
    <other_name>Leukerin</other_name>
    <other_name>Leupurin</other_name>
    <other_name>Mercaleukim</other_name>
    <other_name>Mercaleukin</other_name>
    <other_name>Mercaptina</other_name>
    <other_name>Mercaptopurinum</other_name>
    <other_name>Mercapurin</other_name>
    <other_name>Mern</other_name>
    <other_name>NCI-C04886</other_name>
    <other_name>Puri-Nethol</other_name>
    <other_name>Purimethol</other_name>
    <other_name>Purine, 6-mercapto-</other_name>
    <other_name>Purine-6-thiol (8CI)</other_name>
    <other_name>Purine-6-thiol, monohydrate</other_name>
    <other_name>Purinethiol</other_name>
    <other_name>Purinethol</other_name>
    <other_name>U-4748</other_name>
    <other_name>WR-2785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>3H-Purine-6-thiol</other_name>
    <other_name>6 MP</other_name>
    <other_name>6 Thiohypoxanthine</other_name>
    <other_name>6 Thiopurine</other_name>
    <other_name>6-Mercaptopurine</other_name>
    <other_name>6-Mercaptopurine Monohydrate</other_name>
    <other_name>6-MP</other_name>
    <other_name>6-Purinethiol</other_name>
    <other_name>6-Thiopurine</other_name>
    <other_name>6-Thioxopurine</other_name>
    <other_name>6H-Purine-6-thione, 1,7-dihydro- (9CI)</other_name>
    <other_name>7-Mercapto-1,3,4,6-tetrazaindene</other_name>
    <other_name>Alti-Mercaptopurine</other_name>
    <other_name>Azathiopurine</other_name>
    <other_name>BW 57-323H</other_name>
    <other_name>Flocofil</other_name>
    <other_name>Ismipur</other_name>
    <other_name>Leukerin</other_name>
    <other_name>Leupurin</other_name>
    <other_name>Mercaleukim</other_name>
    <other_name>Mercaleukin</other_name>
    <other_name>Mercaptina</other_name>
    <other_name>Mercaptopurinum</other_name>
    <other_name>Mercapurin</other_name>
    <other_name>Mern</other_name>
    <other_name>NCI-C04886</other_name>
    <other_name>Puri-Nethol</other_name>
    <other_name>Purimethol</other_name>
    <other_name>Purine, 6-mercapto-</other_name>
    <other_name>Purine-6-thiol (8CI)</other_name>
    <other_name>Purine-6-thiol, monohydrate</other_name>
    <other_name>Purinethiol</other_name>
    <other_name>Purinethol</other_name>
    <other_name>U-4748</other_name>
    <other_name>WR-2785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>2-Mercaptoethanesulfonate, Sodium Salt</other_name>
    <other_name>Ausobronc</other_name>
    <other_name>D-7093</other_name>
    <other_name>Filesna</other_name>
    <other_name>Mercaptoethane Sulfonate</other_name>
    <other_name>Mercaptoethanesulfonate</other_name>
    <other_name>Mesnex</other_name>
    <other_name>Mesnil</other_name>
    <other_name>Mesnum</other_name>
    <other_name>Mexan</other_name>
    <other_name>Mistabron</other_name>
    <other_name>Mistabronco</other_name>
    <other_name>Mitexan</other_name>
    <other_name>Mucofluid</other_name>
    <other_name>Mucolene</other_name>
    <other_name>UCB 3983</other_name>
    <other_name>Uromitexan</other_name>
    <other_name>Ziken</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Adlone</other_name>
    <other_name>Caberdelta M</other_name>
    <other_name>DepMedalone</other_name>
    <other_name>Depo Moderin</other_name>
    <other_name>Depo-Nisolone</other_name>
    <other_name>Duralone</other_name>
    <other_name>Emmetipi</other_name>
    <other_name>Esametone</other_name>
    <other_name>Firmacort</other_name>
    <other_name>Medlone 21</other_name>
    <other_name>Medrate</other_name>
    <other_name>Medrol</other_name>
    <other_name>Medrol Veriderm</other_name>
    <other_name>Medrone</other_name>
    <other_name>Mega-Star</other_name>
    <other_name>Meprolone</other_name>
    <other_name>Methylprednisolonum</other_name>
    <other_name>Metilbetasone Solubile</other_name>
    <other_name>Metrocort</other_name>
    <other_name>Metypresol</other_name>
    <other_name>Metysolon</other_name>
    <other_name>Predni-M-Tablinen</other_name>
    <other_name>Prednilen</other_name>
    <other_name>Radilem</other_name>
    <other_name>Sieropresol</other_name>
    <other_name>Solpredone</other_name>
    <other_name>Summicort</other_name>
    <other_name>Urbason</other_name>
    <other_name>Veriderm Medrol</other_name>
    <other_name>Wyacort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>L-Asparaginase with Polyethylene Glycol</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>PEG-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase (Enzon - Kyowa Hakko)</other_name>
    <other_name>PEGLA</other_name>
    <other_name>Polyethylene Glycol L-Asparaginase</other_name>
    <other_name>Polyethylene Glycol-L-Asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione</other_name>
    <other_name>.delta.1-Hydrocortisone</other_name>
    <other_name>Adnisolone</other_name>
    <other_name>Aprednislon</other_name>
    <other_name>Capsoid</other_name>
    <other_name>Cortalone</other_name>
    <other_name>Cortisolone</other_name>
    <other_name>Dacortin H</other_name>
    <other_name>Decaprednil</other_name>
    <other_name>Decortin H</other_name>
    <other_name>Delta(1)Hydrocortisone</other_name>
    <other_name>Delta- Cortef</other_name>
    <other_name>Delta-Cortef</other_name>
    <other_name>Delta-Diona</other_name>
    <other_name>Delta-F</other_name>
    <other_name>Delta-Phoricol</other_name>
    <other_name>Delta1-dehydro-hydrocortisone</other_name>
    <other_name>Deltacortril</other_name>
    <other_name>Deltahydrocortisone</other_name>
    <other_name>Deltasolone</other_name>
    <other_name>Deltidrosol</other_name>
    <other_name>Dhasolone</other_name>
    <other_name>Di-Adreson-F</other_name>
    <other_name>Dontisolon D</other_name>
    <other_name>Estilsona</other_name>
    <other_name>Fisopred</other_name>
    <other_name>Frisolona</other_name>
    <other_name>Gupisone</other_name>
    <other_name>Hostacortin H</other_name>
    <other_name>Hydeltra</other_name>
    <other_name>Hydeltrasol</other_name>
    <other_name>Klismacort</other_name>
    <other_name>Kuhlprednon</other_name>
    <other_name>Lenisolone</other_name>
    <other_name>Lepi-Cortinolo</other_name>
    <other_name>Linola-H N</other_name>
    <other_name>Linola-H-Fett N</other_name>
    <other_name>Longiprednil</other_name>
    <other_name>Metacortandralone</other_name>
    <other_name>Meti Derm</other_name>
    <other_name>Meticortelone</other_name>
    <other_name>Opredsone</other_name>
    <other_name>Panafcortelone</other_name>
    <other_name>Precortisyl</other_name>
    <other_name>Pred-Clysma</other_name>
    <other_name>Predeltilone</other_name>
    <other_name>Predni-Coelin</other_name>
    <other_name>Predni-Helvacort</other_name>
    <other_name>Prednicortelone</other_name>
    <other_name>Prednisolonum</other_name>
    <other_name>Prelone</other_name>
    <other_name>Prenilone</other_name>
    <other_name>Sterane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic Hydrocortisone</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Aeroseb-HC</other_name>
    <other_name>Barseb HC</other_name>
    <other_name>Barseb-HC</other_name>
    <other_name>Cetacort</other_name>
    <other_name>Cort-Dome</other_name>
    <other_name>Cortef</other_name>
    <other_name>Cortenema</other_name>
    <other_name>Cortifan</other_name>
    <other_name>Cortisol</other_name>
    <other_name>Cortispray</other_name>
    <other_name>Cortril</other_name>
    <other_name>Dermacort</other_name>
    <other_name>Domolene</other_name>
    <other_name>Eldecort</other_name>
    <other_name>Hautosone</other_name>
    <other_name>Heb-Cort</other_name>
    <other_name>HYDROCORTISONE</other_name>
    <other_name>Hydrocortone</other_name>
    <other_name>Hytone</other_name>
    <other_name>Komed-HC</other_name>
    <other_name>Nutracort</other_name>
    <other_name>Proctocort</other_name>
    <other_name>Rectoid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>2-Amino 6MP</other_name>
    <other_name>2-Amino-1,7-dihydro-6H-purine-6-thione</other_name>
    <other_name>2-Amino-6-mercaptopurine</other_name>
    <other_name>2-Amino-6-purinethiol</other_name>
    <other_name>2-Aminopurin-6-thiol</other_name>
    <other_name>2-Aminopurine-6(1H)-thione</other_name>
    <other_name>2-Aminopurine-6-thiol</other_name>
    <other_name>2-Mercapto-6-aminopurine</other_name>
    <other_name>6-Amino-2-mercaptopurine</other_name>
    <other_name>6-Mercapto-2-aminopurine</other_name>
    <other_name>6-Mercaptoguanine</other_name>
    <other_name>6-TG</other_name>
    <other_name>6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)</other_name>
    <other_name>BW 5071</other_name>
    <other_name>Lanvis</other_name>
    <other_name>Tabloid</other_name>
    <other_name>Tioguanin</other_name>
    <other_name>Tioguanine</other_name>
    <other_name>Wellcome U3B</other_name>
    <other_name>WR-1141</other_name>
    <other_name>X 27</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (imatinib mesylate, EsPhALL chemotherapy)</arm_group_label>
    <arm_group_label>Arm B (imatinib mesylate, COG/BFM chemotherapy)</arm_group_label>
    <arm_group_label>Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have not previously enrolled on AALL08B1 or APEC14B1 (if open for
             classification of newly diagnosed ALL patients) prior to enrollment on AALL1631, a
             baseline diagnostic sample must be available to develop an MRD probe

          -  Newly diagnosed de novo ALL (B-ALL or T-ALL) with definitive evidence of BCR-ABL1
             fusion by karyotype, fluorescence in situ hybridization (FISH) and/or reverse
             transcriptase (RT)-PCR

               -  For patients who DO NOT enter AALL1631 via AALL08B1 or APEC14B1 (if open for
                  classification of newly diagnosed ALL patients), laboratory reports detailing
                  evidence of BCR-ABL1 fusion must be submitted for rapid central review within 72
                  hours of study enrollment

               -  Patients with known chronic myelogenous leukemia (CML) who develop lymphoid
                  blast crisis are not eligible

          -  Patient must have previously started induction therapy, which includes vincristine, a
             corticosteroid, pegaspargase, with or without anthracycline, and/or other standard
             cytotoxic chemotherapy

          -  Patient has not received more than 14 days of induction therapy

          -  Patient has not had prior treatment with imatinib, dasatinib, or any other BCR-ABL1
             inhibitor

          -  Karnofsky/Lansky performance status &gt;= 60; use Karnofsky for patients &gt; 16 years of
             age and Lansky for patients =&lt; 16 years of age

          -  Direct bilirubin =&lt; 2.0 mg/dL

          -  Shortening fraction of &gt;= 27% by echocardiogram

          -  Ejection fraction of &gt;= 50% by radionuclide angiogram or echocardiogram

          -  Corrected QT interval, QTc &lt; 480 msec

               -  Note: Repeat echocardiogram is not required if echocardiogram was obtained
                  within 21 days of study enrollment

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             mL/min/1.73 m^2

          -  Serum creatinine within normal limits based on age/gender, as follows:

               -  1 to &lt; 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)

               -  2 to &lt; 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)

               -  6 to &lt; 10 years: maximum serum creatinine 1 mg/dL (both male and female)

               -  10 to &lt; 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)

               -  13 to &lt; 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)

               -  &gt;= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)

        Exclusion Criteria:

          -  Known history of chronic myelogenous leukemia (CML)

          -  ALL developing after a previous cancer treated with cytotoxic chemotherapy

          -  Active, uncontrolled infection, or active systemic illness that requires ongoing
             vasopressor support or mechanical ventilation

          -  Down syndrome

          -  Pregnancy and breast feeding

               -  Female patients who are pregnant; a pregnancy test is required for female
                  patients of childbearing potential

               -  Lactating females who plan to breastfeed their infants

               -  Sexually active patients of reproductive potential who have not agreed to use an
                  effective contraceptive method for the duration of their study participation

          -  Patients with congenital long QT syndrome, history of ventricular arrhythmias or
             heart block

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis Silverman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lewis B. Silverman</last_name>
      <phone>877-442-3324</phone>
    </contact>
    <investigator>
      <last_name>Lewis B. Silverman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>December 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>2-Aminopurine</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
